Log in to search using one of your social media accounts:

 

Danazol as first-line therapy for myelodysplastic syndromes

At present, no standard therapy is available for most patients with myelodysplastic syndromes. In this retrospective study, we analyse data from 42 patients with myelodysplastic syndrome treated with low-dose danazol. More than half achieved a response. Results show that danazol remains an attractive option due to its low cost and good safety profile in centers with reduced access to novel therapeutic alternatives.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

Several prognostic factors such as intermediate karyotype, presence of 5-9% bone marrow blasts and platelet count
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
This report adds to the pool of cases that reveal associations between use of lenalidomide and increased risk of developing secondary primary high-grade astrocytomas in multiple myeloma. PMID: 29616908 [PubMed - in process]
Source: The Permanente journal - Category: General Medicine Tags: Perm J Source Type: research
Publication date: Available online 8 February 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Jill A. Bell, Aaron Galaznik, Rachel Huelin, Michael Stokes, Yelan Guo, Robert J. Fram, Douglas V. Faller High-dose chemotherapy with allogeneic hematopoietic stem cell transplantation (allo-HSCT) can produce long-term remission in patients with higher-risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML). However, this treatment regimen is not appropriate for elderly and/or comorbid patients; in these cases, azacitidine is a standard treatment. This systematic review was conducted to ev...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 8 February 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Riad El Fakih, Rami Komrokji, Marwan Shaheen, Fahad Almohareb, Walid Rasheed, Mona Hassanein Azacitidine and decitabine are hypomethylating agents frequently used interchangeably to treat myeloid neoplasms in different settings. Azacitidine is metabolized intracellularly into decitabine. Hypomethylating agents work by inhibiting DNA methyltransferases, causing demethylation of aberrantly methylated promoter regions of genes involved in the pathogenesis of myeloid neoplasms. Azacitidine was the first agent approved b...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
High-dose chemotherapy with allogeneic hematopoietic stem cell transplantation (allo-HSCT) can produce long-term remission in patients with higher risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML). However, this treatment regimen is not appropriate for elderly and/or comorbid patients; in these cases, azacitidine is a standard treatment. This systematic review was conducted to evaluate real-world evidence of treatment options for patients with HR-MDS/CMML.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
High-dose chemotherapy with allogeneic hematopoietic stem cell transplantation (allo-HSCT) can produce long-term remission in patients with higher-risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML). However, this treatment regimen is not appropriate for elderly and/or comorbid patients; in these cases, azacitidine is a standard treatment. This systematic review was conducted to evaluate real-world evidence of treatment options for patients with HR-MDS/CMML. Medline and Embase (January 2006 to May 2016) were searched, in addition to conference proceedings and treatment guideline reviews.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Source Type: research
Background: Melphalan exposure as measured by area under the curve (AUC) has a 5-fold variability between pts, with higher AUCs associated with improved outcomes but increased toxicity (Shaw BBMT 2012). Evomela ® (propylene glycol free melphalan, PGF-MEL) is an intravenous formulation with improved stability and possibly less toxicity related to the solubilizing agent. We aimed to determine the pharmacokinetics (PK) and relationship between exposure and toxicities with this formulation in order to optimiz e dosing.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
CONCLUSION Cognitive impairment can affect daily functioning, quality of life, and capacity to work in patients with cancer and those in remission. Consequently, cognitive assessment is now an important and necessary part of a comprehensive oncological care plan. Cancer-related cognitive impairment might be due to the direct effects of the cancer itself, nonspecific factors, or comorbid conditions that are independent of the disease and/or due to the adverse effects of the treatment or combination of treatments given for the disease. The prevalence and extent of cognitive impairment associated with cancer is recognized but...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Cognition Current Issue Neuro oncology Neurology Review cancer chemotherapy cognitive impairment neuropsychological assessment treatment Source Type: research
The majority of blood cancers occur in the elderly. This fact conspires with an aging population in many countries to make rigorous assessment for frailty increasingly important for hematologic oncologists. In this review, we first define frailty and its relevance for patients with hematologic malignancy. Next, we review current data regarding the effect of domains of frailty on outcomes for blood cancers including myelodysplastic syndromes, acute leukemia, non-Hodgkin lymphomas such as chronic lymphocytic leukemia, and multiple myeloma. Finally, after presenting assessment and treatment options for the practicing hematolo...
Source: Blood - Category: Hematology Authors: Tags: Free Research Articles, Myeloid Neoplasia, Lymphoid Neoplasia, Review Articles, Review Series, Clinical Trials and Observations Source Type: research
Conclusion Lenalidomide did not adversely affect HRQoL in RBC-TD patients with lower-risk non-del(5q) MDS and response to lenalidomide was associated with significant improvements in HRQoL. Teaser HRQoL was evaluated among RBC-TD patients with lower-risk non-del(5q) MDS treated with lenalidomide (n = 160) or placebo (n = 79) in the phase 3 MDS-005 study. Lenalidomide did not worsen HRQoL; response to lenalidomide was associated with significant HRQoL improvement. Lenalidomide represents a treatment option for patients with lower-risk non-del(5q) MDS who are ineligible for or refractory to ESAs.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Hematology | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Study